What's The Future of Cancer Immunotherapy? World Renowned Cancer Expert Shares His Perspective

curncman
Posts: 1313
Joined: Fri Jun 26, 2020 8:27 am

Parallel CAR T-Cell Immunotherapy of Solid Tumours by John Maher

Post by curncman »

Parallel CAR T-Cell Immunotherapy of Solid Tumours by John Maher


curncman
Posts: 1313
Joined: Fri Jun 26, 2020 8:27 am

World CRISPR Day 2021 - Session 1 - Cell & Gene Therapy

Post by curncman »

World CRISPR Day 2021 - Session 1 - Cell & Gene Therapy


curncman
Posts: 1313
Joined: Fri Jun 26, 2020 8:27 am

CAR-Ts, NKs, Gene editing: Past, Present and Future of Cell Therapies for Immuno-Oncology

Post by curncman »

CAR-Ts, NKs, Gene editing: Past, Present and Future of Cell Therapies for Immuno-Oncology
Justin Eyquem is quite a unique witness of the emergence of CAR-T cell therapies. He did his PhD in partnership with CAR-T company Cellectis. In 2014, he joined the lab of Michel Sadelain at the MSKCC, who co-founded Juno Therapeutics and is now involved with leading CAR-T cell companies such as Fate Therapeutics and Atara Biotherapeutics. Justin eventually established his own lab at USCF and co-founded Mnemo Therapeutics with Michel Sadelain in 2018. In this episode, we talk about his experience, lessons learned from the first wave of CAR-T cell therapies, as well as the future of the field (NKs, allogeneic strategies, multiplexed gene editing, combinatorial approaches, and more). A great episode !


curncman
Posts: 1313
Joined: Fri Jun 26, 2020 8:27 am

Nektar Therapeutics 2022 J P Morgan Presentation

Post by curncman »

Nektar Therapeutics 2022 J P Morgan Presentation

curncman
Posts: 1313
Joined: Fri Jun 26, 2020 8:27 am

TC BioPharm to Participate in Advanced Therapies Week January 25-28

Post by curncman »

TC BioPharm to Participate in Advanced Therapies Week January 25-28

Tue, January 18, 2022, 8:30 AM·3 min read
EDINBURGH, Scotland, Jan. 18, 2022 /PRNewswire/ -- TC BioPharm (Holdings) Limited ("TC BioPharm"), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications announced today that Executive Chairman and Founder, Dr. Michael Leek will be participating in Advanced Therapies Week in Miami, Florida January 25-28.

Michael will participate in a session titled, Treating Cancer and Covid – Use of Banked Allogeneic Gamma-Delta T Cells in Oncology and Severe Vital Infection. The presentation will take place on Friday January 28th at 9:50 am ET at the Miami Beach Convention Centre. For more information or to register for the event, please visit; https://advancedtherapiesweek.phacilitate.com/

Dr. Michael Leek has 30 years' experience in regenerative medicine, during which he progressed 10 different cell-based products from the laboratory into clinic. In 2017, Michael received the 'Scottish Life-Sciences Entrepreneurial Business Leadership' award for 2016-2017. Michael is also a Fellow of the Royal Society of Medicine and Honorary Lecturer at the University of Aberdeen, School of Medical Sciences.

Advanced Therapies Week is a large and immersive expo for companies in the cell and gene therapy sector. It has a focus on knowledge sharing, relationship building and deal making to advance a major pillar of medicine.
Post Reply